Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice

Fig. 4

Hind paws from a vehicle control animal have mild inflammation and very minimal cartilage damage in a few digit joints. Arrows identify representative affected joints/regions (a). Hind paws from an arthritic animal treated with 50 mg/kg of takinib have very minimal inflammation in the ankle only (b). Reduction of inflammation (I), pannus (P), cartilage damage (CD), bone resorption (BR), and periosteal bone formation (PB) were seen in the hind paws of vehicle- and takinib-treated animals (c, d). Forepaw from a vehicle control animal has severe inflammation and mild cartilage damage with minimal pannus, bone resorption, and periosteal bone formation, in all joints. Arrows identify representative affected joints. “W” identifies wrist (e). Forepaw from an arthritic animal treated with 50 mg/kg of takinib has inflammation and cartilage damage with moderate pannus, bone resorption, and periosteal bone formation, in all joints. Arrows identify representative affected joints (f). Reduction of inflammation (I), pannus (P), cartilage damage (CD), bone resorption (BR), and periosteal bone formation (PB) were seen in the forepaw of vehicle- and takinib-treated animals (g, h). All images represent animal with approximate mean summed paw score for the group. n = 9–12 ± SEM/vehicle disease control and takinib groups. Two-way ANOVA, Dunnett’s post hoc. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page